1. Introduction
===============

Porcine reproductive and respiratory syndrome virus (PRRSV) is a positive stranded RNA virus that causes reproductive failure in late term gestation sows and respiratory disease in pigs of all ages. The virus primarily infects and destroys alveolar macrophages, which are important in the host defence in the lungs. Therefore, PRRSV-infected pigs may be more susceptible to secondary infections. Since PRRSV occurs endemically in many countries and may influence the efficacy of host defence mechanisms, it is possible that a PRRSV infection interferes with the vaccination efficacy against PRV.

Previous studies on the effect of PRRSV infection on secondary infections under experimental conditions are contradictory. [@BIB6] described more clinical signs, meningitis and bacteraemia after a *Streptococcus suis* infection only when pigs were pre-inoculated with PRRSV. [@BIB18] described more severe and persistent pneumonic lesions and clinical respiratory disease when a *Mycoplasma hyopneumoniae* infection was followed by a PRRSV infection. [@BIB19], [@BIB20] described more severe disease after a dual infection with PRRSV and porcine respiratory coronavirus or influenza virus compared with the single infections. In contrast, others described no influence of a PRRSV infection on the clinical signs of disease after infection with *Pasteurella multocida*, *Haemophilus parasuis*, *S. suis* or *Salmonella cholerasuis* ([@BIB3]). In addition, [@BIB1] could not demonstrate an immunosuppressive effect of PRRSV on a pseudorabies virus (PRV) glycoprotein immunisation and described an enhanced antibody response after challenge with PRV.

More illness and a more severe disease outcome after infection with other micro-organisms due to an earlier PRRSV infection have been described. These studies focussed on increased illness and pathological alterations by the secondary infection in PRRSV-infected pigs. However, the effect of PRRSV on the cellular immune response against secondary infections is not clear. Therefore, we examined the effects of a PRRSV infection on the development of the cellular immune response against a PRV infection in a well-defined PRV vaccination-challenge model.

PRV is an alphaherpesvirus that causes Aujeszky's disease in pigs. Both humoral and cellular immunity appear to be involved in the development of a protective immune response to PRV. Previous reports have described the time course of the lymphoproliferative and cytolytic responses after a PRV infection and challenge in detail ([@BIB12], [@BIB4]). Therefore, we used this PRV model to investigate the immunosuppressive effect of PRRSV on a PRV vaccination and challenge in pigs. We investigated the development of the humoral, lymphoproliferative and cytolytic responses against PRV in pigs that were inoculated with PRRSV prior to PRV vaccination.

2. Materials and methods
========================

2.1. Viruses
------------

PRRSV stocks for inoculation were prepared on alveolar macrophages as described by [@BIB21]. Pigs were inoculated with PRRSV strain Lelystad virus ter Huurne (LV-TH). PRV stocks for vaccination and challenge were prepared on SK-6 cells ([@BIB8]) and secondary porcine kidney cells, respectively, as described by [@BIB12]. Pigs were vaccinated with an avirulent mutant strain M141 (gE^−^) of PRV ([@BIB5], [@BIB9]). The pigs were then challenged with wild-type PRV strain NIA-3 ([@BIB13]). This strain was also used to infect target cells for the cytolytic assay, as described by [@BIB11].

2.2. Animals and experimental design
------------------------------------

Minnesota miniature pigs from our institute, which are inbred for swine--leukocyte--antigen complex (SLA) (haplotype d/d) ([@BIB16]), were kept under specific pathogen-free conditions. The pigs were born from unvaccinated sows and had no antibodies against PRV or PRRSV. Pigs were randomly allocated to two groups and housed separately. Six pigs were intranasally inoculated with 0.5 ml of PRRSV strain LV-TH at a concentration of 10^5^  TCID~50~/ml per nostril. Five control SPF pigs were left uninoculated. After 2 weeks both groups were vaccinated intramuscularly with 10^5^  plaque-forming units (PFU)/ml PRV strain M141. These pigs were subsequently challenged intranasally with 10^5^  PFU/ml NIA-3 virus, 8 weeks after PRV vaccination. Blood samples were taken weekly, starting 1 week before and then 2 weeks after the LV inoculation. Rectal temperatures were recorded daily for 25 days after LV inoculation and 25 days after PRV challenge. Body weights were recorded at weekly intervals for 3 months. Pigs were considered to have fever when body temperatures were above or equal to 40°C. Growth performance was assessed by calculating the mean relative daily gain (MRDG) in body weight according to [@BIB17]. The ethical committee for animal experiments of ID-Lelystad approved the experiments ([Table 1](#TBL1){ref-type="table"} ).Table 1Experimental designLV inoculationM141 vaccinationNIA-3 challengePRV (*n*=5)ND2 weeks10 weeksLV-PRV (*n*=6)Day 02 weeks10 weeks

2.3. Isolation and culture of PBMC
----------------------------------

PBMC isolation and culturing was done as previously described by [@BIB12]. Briefly, PBMC were stimulated in vitro for 4 days with negative cell-lysate of SK-6 cells, or infectious NIA-3 (PRV) virus. For cytolytic assays, PBMC were used directly (direct killing) or they were stimulated for 6 days in vitro with NIA-3 (indirect killing) as described by [@BIB4].

2.4. Lymphocyte proliferation assay
-----------------------------------

Proliferation of PBMC was measured by ^3^H-thymidine incorporation as described by [@BIB4] and expressed as delta counts, i.e. the number of counts of virus-stimulated PBMC minus the number of counts of negative cell-lysate-stimulated PBMC. Proliferation was investigated starting 1 week before LV inoculation and then at weekly intervals from 2 weeks after LV inoculation and was measured after subsequent PRV inoculations.

2.5. Target cells
-----------------

The following target cells were used in the cytolytic assays: PRV-infected and uninfected L14 cells (a retrovirus immortalised B-lymphoblastoid cell line of the haplotype d/d SLA) ([@BIB7]) and K562 cells (a cell line from human erythroleukemia cells) (ATCC, Rockville, MD). The K562 cells were used to assess the killing by porcine NK cells ([@BIB15]). Infected L14 cells were obtained by infecting the cells, 24 h before the start of the cytolytic assay, with NIA-3 virus at a multiplicity of infection of 10. The cells were labelled by incubation of various numbers of cells in a volume of 50 μl serum-free medium which contained 400 μCi 51Cr (Amersham CJS4, Den Bosch, The Netherlands) for 2 h at 37°C on a Rock'n Roller (Labinco, Breda, The Netherlands). After being labelled, the cells were washed three times in RPMI complete medium. Volumes of 50 μl medium containing 10^4^ cells were added to the wells of 96-well V-bottomed microtitre plates (Nunc, Life Technology, Breda, The Netherlands).

2.6. Cytolytic assay
--------------------

The cytolytic activity of the effector cells was measured by 51Cr release. Volumes of 50 μl medium containing effector cells and 50 μl medium containing 10^4^ 51Cr-labelled target cells were mixed in order to obtain effector:target ratios of 50:1 to 6:1. The plates were then centrifuged for 5 min at 200×*g*. Maximal release of 51Cr was determined by adding 50 μl 20% Triton X-100. Spontaneous release was determined in wells that did not contain effector cells. Killing of the target cells was determined by measuring the release of 51Cr in the supernatant after an incubation period of 5 h. Volumes of 50 μl supernatant were mixed with 100 μl optiphase supermix liquid scintillation fluid (EG&G Instruments, Nieuwegein, The Netherlands). Radioactivity was then measured in a Wallac Microbetaplus 1450 (EG&G Instruments, Nieuwegein, The Netherlands). The percentage of specific 51Cr release was calculated as

Direct killing was investigated at 10 and 18 days after PRV vaccination. Indirect killing was investigated 1 week before the LV inoculation and then 2 weeks after LV inoculation and was measured at weekly intervals after subsequent PRV inoculations.

2.7. Serological examinations
-----------------------------

Blood samples were collected from all pigs 1 day before LV inoculation and at weekly intervals after PRV inoculations. Serum samples were stored at −20°C. Sera were tested for the presence of virus neutralising antibodies directed against PRV in a virus neutralisation test (VN titres) as described by [@BIB9]. Sera were tested for the presence of virus antibodies directed against PRRSV in an immunoperoxidase monolayer assay (IPMA) and for the presence of PRRSV by virus isolation as described by [@BIB21].

2.8. PRV isolation
------------------

PRV virus excretion was monitored by collecting swab specimens of oropharyngeal fluid (OPF) from the day before challenge until day 10 after challenge. Swab specimens were extracted with 4 ml of Dulbecco's minimal essential medium supplemented with 2% foetal bovine serum and antibiotics. To determine the virus content per gram OPF, we measured the weight of the collected fluid after centrifugation of the swabs ([@BIB9]). The amount of PRV excretion was quantitated by titration of the virus on SK-6 monolayers as described by [@BIB9].

2.9. Statistical analysis
-------------------------

Differences in lymphoproliferative responses, virus-specific killing activity, VN antibody titres and MRDG were tested for statistical significance by analysis of variance (ANOVA) after testing for homogeneity of variances within groups (Barletts' test). The significance level was set at 5%.

3. Results
==========

3.1. Time course of the humoral response against LV and PRV
-----------------------------------------------------------

LV specific antibodies were detected from 1 week after LV inoculation in IPMA. This response peaked on 7 weeks after LV inoculation (titre log 4.6) and declined thereafter. After 15 weeks post-LV inoculation, antibodies against LV (titre log 3.4) were still detected.

PRV VN antibodies were detected from 1 week after PRV vaccination with M141 (gE^−^ PRV-strain), in the LV-PRV and the PRV group, with a virus neutralisation assay (titres log 2.7−3.3). After challenge with PRV, no increase of the antibody-titres was observed and no difference was observed in the development of the humoral response between both groups. In contrast to the antibody-titres against LV, the antibody-titres after PRV vaccination and challenge did not decrease during the experiment (15 weeks).

3.2. Time course of the lymphoproliferative response against PRV
----------------------------------------------------------------

One week after PRV vaccination, PBMC from PRV-infected pigs proliferated abundantly in vitro in both groups on stimulation with PRV ([Fig. 1](#FIG1){ref-type="fig"} ). The proliferation of PBMC tended to be higher (but not statistically significantly) in the PRV group (50,587±36,565 CPM) than in the LV-PRV group (18,042±19,888 CPM) (*P*\<0.09). The response peaked 2 weeks after PRV vaccination in both groups. In the LV-PRV group the lymphoproliferative response declined 1 week later, whereas in the PRV group the lymphoproliferative response remained high for 3 weeks and declined thereafter. The proliferation was significantly higher (*P*\<0.05) in the PRV group than in the LV-PRV group in weeks 4 and 5 after PRV vaccination. In contrast to the VN antibodies, the lymphoproliferative response increased after challenge with wild-type NIA-3 virus ([Fig. 1](#FIG1){ref-type="fig"}) in both groups. This secondary lymphoproliferative response started 1 week after challenge in the PRV group and 2 weeks after challenge in the LV-PRV group (*P*\<0.05). After PRV challenge, the specific proliferation of PBMC to PRV stimulation was consistently and significantly lower, in the LV-PRV group than in the PRV group (*P*\<0.05) ([Fig. 1](#FIG1){ref-type="fig"}).Fig. 1Time course of PRV-specific lymphoproliferation after inoculation with PRRSV and PRV. PBMC isolated from inoculated SLA d/d minipigs were stimulated in vitro with PRV for 4 days. Presented are delta counts, i.e. ^3^H-thymidine incorporation (CPM) of PRV-stimulated PBMC minus ^3^H-thymidine incorporation (CPM) of negative-cell-lysate-stimulated PBMC. The open arrow indicates inoculation with PRRSV. Closed arrows indicate PRV vaccination and challenge. Significant differences are indicated with an asterisk (*P*\<0.05).

3.3. Time course of cytolytic activity
--------------------------------------

### 3.3.1. Indirect killing after LV and PRV inoculations:

When PBMC from the PRV and LV-PRV group were stimulated in vitro with NIA-3 virus, PRV-specific killing (i.e. killing of PRV-infected L14 cells and killing of uninfected L14 cells) increased between weeks 3 and 6 after PRV vaccination (up to 30% of PRV-infected target cells were killed compared with up to 15% of uninfected target cells). In both groups, PRV-specific killing by these cells was detected for a period of at least 6 weeks after challenge; (up to 35% of PRV-infected target cells were killed compared with up to 15% of uninfected target cells). K562 cells were only poorly killed (10% after PRV vaccination). The PRV-specific killing was higher at 3 weeks after PRV vaccination and 5 weeks after PRV challenge 19±3 and 24±6%, respectively, in the PRV group, compared to 7±4 and 6±9%, respectively, in the LV-PRV group (*P*\<0.05) ([Fig. 2](#FIG2){ref-type="fig"} ). However, later after PRV vaccination the killing was comparable in both groups. K562 cells were poorly killed in both groups (up to 20% in the PRV and LV-PRV group 1 week after challenge).Fig. 2Time course of PRV-specific killing, i.e. killing of PRV-infected target cells minus killing of uninfected target cells. PBMC from inoculated SLA d/d minipigs were stimulated in vitro with PRV for 6 days and incubated for 5 h with PRV-infected or uninfected 51Cr-labelled target L14 cells. The open arrow indicates inoculation with PRRSV. Closed arrows indicate PRV vaccination and challenge. Significant differences are indicated with an asterisk (*P*\<0.05).

### 3.3.2. Direct killing after PRV vaccination:

On day 10 after PRV vaccination, directly used PBMC from the PRV group killed the PRV-infected L14 cells more efficiently (30±5%) than PBMC from the LV-PRV group (18±7%) (*P*\<0.05). In contrast, on day 18 after PRV vaccination, PBMC from the PRV and LV-PRV group killed the PRV-infected L14 cells equally well (14±5%) and (11±4%). No killing of K562 cells was detected.

3.4. Daily body temperature, virus isolation, clinical signs and MRDG
---------------------------------------------------------------------

Pigs from the LV-PRV group had fever after inoculation with LV from days 3 to 6 after LV inoculation and again after PRV vaccination on days 17 and 18 after LV infection. In contrast, pigs from the PRV group had no fever after vaccination ([Fig. 3](#FIG3){ref-type="fig"} ). Pigs from both groups had no fever after challenge. LV was isolated from sera from 4 pigs (*n*=6). LV was isolated on day 3 (2 pigs), day 10 (1 pig) and day 24 (1 pig) after LV inoculation. No PRV was isolated from OPF of both groups after challenge with PRV. The mean daily weight gain did not differ after LV and after both PRV inoculations between both groups. Pigs had no clinical signs of PRRSV disease after LV inoculation (except fever) and no clinical signs of Aujeszky's disease after PRV inoculations.Fig. 3Body temperature curve of inoculated pigs during 25 days after LV inoculation and subsequent PRV vaccination. An open arrow indicates inoculation with PRRSV and a closed arrow indicates vaccination with PRV. Fever (\>40°C) is indicated with an asterisk.

4. Discussion
=============

Results showed that a PRRSV infection prior to a PRV vaccination caused differences in the level and time course of the cellular immune response against PRV. The lymphoproliferative response tended to be quicker (not significantly) and longer (2 weeks) (*P*\<0.05) in the PRV group than in the LV-PRV group after PRV vaccination. This lymphoproliferative response was also quicker (1 week) and consistently higher in the PRV group than in the LV-PRV group after PRV challenge (*P*\<0.05). Furthermore, when we used in vitro PRV-stimulated PBMC, the cytolytic response against PRV reached a maximum in week 3 after PRV vaccination and week 5 after PRV challenge in the PRV-group, whereas the LV-PRV group did not (*P*\<0.05). Later after vaccination and challenge, the cytolytic response was comparable in both groups. The same kinetics of the cytolytic response against PRV vaccination with M141 was described in an other study ([@BIB4]), which indicates that the LV-PRV group in this study did not reach a maximum level in the cytolytic response, whereas the PRV group did. When PBMC were used directly, we also observed a significantly higher cytolytic response against PRV on day 10 after PRV vaccination in the PRV group than in the LV-PRV group (*P*\<0.05). These results indicate a mild immunosuppressive effect by the PRRSV infection on the development of a cellular immune response after PRV vaccination and challenge. An explanation for this lower T-lymphocyte response may be that PRRSV infects monocytes and macrophages, which may hamper efficient antigen-presentation and thereby suppressing the ability of PBMC to proliferate.

Although PRRSV clearly affected the time course of the cellular immune response against a PRV infection, no effect on the humoral response against PRV was detected after vaccination and challenge in the LV-PRV group. This finding is in contrast to [@BIB2], who observed an enhanced secondary humoral response after an influenza challenge, and [@BIB1] and [@BIB14], who also observed an enhanced humoral response after challenge with PRV, after an earlier PRRSV infection. It is possible that PRRSV infection stimulates the humoral response. However, an explanation for this discrepancy is that we used a very potent vaccine strain, inducing protection and no increase of antibody-titres ([@BIB9], [@BIB10], [@BIB4]). We could not detect differences in protection against a PRV challenge between both groups, but a negative effect of a PRRSV infection on protection after PRV vaccination can not be excluded when less potent vaccine strains are used. However, the M141 vaccine strain was used, because this strain induced a high cellular immune response ([@BIB4]) and eventually negative effects of a PRRSV infection on the development of the cellular immune response could be measured very well.

No weight loss or differences in mean daily weight gain were observed between both groups. Furthermore, no PRV was excreted after challenge indicating optimal protection. The only observed clinical signs were fever for 4 days after LV inoculation and again 2 days after the PRV vaccination in LV-PRV group. [@BIB19] also described fever and more clinical signs after dual infections of PRRSV with porcine respiratory coronavirus and swine influenza virus. Although we measured fever after LV inoculation and PRV vaccination, we could not detect clinical signs of Aujeszky's disease after vaccination with M141 (a PRV mutant strain that causes mild clinical signs ([@BIB10], [@BIB4])). Obviously, even though pigs were recovering from the earlier PRRSV infection, the PRV mutant strain M141 could not cause Aujeszky's disease. Thus, although T-lymphocyte responses were diminished against PRV, and pigs had some fever in the LV-PRV group, pigs were clinically protected against a PRV challenge.

In conclusion, we demonstrated that a PRRSV infection prior to a PRV vaccination mildly affects the level and time course of the T-lymphocyte response against PRV. Despite this difference, the PRRSV infection did not influence the capacity of the gE^−^ PRV strain to induce protection against a wild-type PRV challenge.
